news

  • 25 April 2019
    Genkyotex provides Corporate Update and Reports Cash position at March 31, 2019

    Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today provided a corporate update, and reported cash and cash equivalents of 7.3 million, at March 31, 2019.

    Elias Papatheodorou, CEO of Genkyotex, commented: “In the first quarter of 2019, the treatment period of the Phase 2 PBC trial was completed and we expect final top-line data to be available in early May. Importantly, the interim efficacy results presented at the International Liver Conference (ILC) earlier this month support the anti-inflammatory and anti-fibrotic mechanism of action of GKT831.”

    “We look forward to the initiation of the Phase 2 NIH funded trial in Idiopathic Pulmonary Fibrosis (IPF), which is expected in the coming months,” continued Mr. Papatheodorou. “We are excited about the broad therapeutic potential of GKT831 in multiple inflammatory / fibrotic diseases. Furthermore, our cash position allows us to confirm our financial visibility until April 2020.”

    Download the full press release